GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
Form 8-K Monte Rosa Therapeutics, For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.